MedTrace Logo

Sperm Epigenome in Hodgkin Lymphoma

NCT07449832 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-14

No results posted yet for this study

Summary

Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.

We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.

Conditions

  • Hodgkin Disease Lymphoma

Interventions

OTHER

Additional semen samples

5 additional semen samples : before chemotherapy, at month 6, 12, 18 and 24 after chemotherapy. Each sperm sample will be stored in liquid nitrogen and sent to Institut National de la Recherche Scientifique (INRS), Quebec, Canada for epigenetic analysis.

Sponsors & Collaborators

  • Institut National de la Recherche Scientifique - Centre Armand Frappier Santé Biotechnologie

    collaborator UNKNOWN

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Géraldine DELBES, PhD · Institut National de la Recherche Scientifique (INRS), Québec, Canada

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2030-01-01
Completion
2030-01-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07449832 on ClinicalTrials.gov